<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681457</url>
  </required_header>
  <id_info>
    <org_study_id>CLJN452A2109</org_study_id>
    <nct_id>NCT03681457</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of Tropifexor (LJN452) in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effect of hepatic impairment on the&#xD;
      systemic exposure of tropifexor and to evaluate the safety of tropifexor in subjects with&#xD;
      hepatic impairment. The results of this study will support treatment and dosing decisions for&#xD;
      patients with varying degrees of hepatic impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">September 25, 2019</completion_date>
  <primary_completion_date type="Actual">September 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The maximum (peak) observed drug concentration after single dose administration (mass x volume-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Time to reach the maximum (peak) plasma drug concentration after single dose administration (time)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The area under the concentration-time curve from time zero to the time of the last quantifiable concentration sampling time (mass x time x volume-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The area under the concentration-time curve from time zero to infinity (mass x time x volume-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The apparent total body clearance of the drug from plasma (volume x time-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The apparent volume of distribution during the terminal phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fu</measure>
    <time_frame>Day 1</time_frame>
    <description>Fraction of analyte unbound calculated in-vitro</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,u</measure>
    <time_frame>Day 1</time_frame>
    <description>The maximum (peak) observed plasma drug concentration after single dose administration (Cmax) of unbound drug (mass x time x volume-1), calculated as Cmax*fu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast,u</measure>
    <time_frame>Day 1</time_frame>
    <description>The area under the concentration-time curve from time zero to the last quantifiable concentration sampling time of unbound drug (mass x time x volume-1), calculated as AUClast*fu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,u</measure>
    <time_frame>Day 1</time_frame>
    <description>The area under the concentration-time curve from time zero to infinity of unbound drug (mass x time x volume-1), calculated as AUCinf*fu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,u</measure>
    <time_frame>Day 1</time_frame>
    <description>The apparent total body clearance of drug from the plasma of unbound drug (volume x time-1), calculated as CL/F/fu</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Group 1 - Normal Hepatic Function</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal hepatic function - Control - control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild hepatic impairment - Child-Pugh A (Score 5-6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hepatic impairment - Child-Pugh B (Score 7-9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe hepatic impairment - Child-Pugh C (score 10-15)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LJN452</intervention_name>
    <description>Dose A single dose</description>
    <arm_group_label>Group 1 - Normal Hepatic Function</arm_group_label>
    <arm_group_label>Group 2 - Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Group 3 - Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Group 4 - Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All subjects:&#xD;
&#xD;
        Inclusions Criteria:&#xD;
&#xD;
          -  Subjects must weight at least 50 kg, with a BMI within the range of 18 to 38 kg/m2&#xD;
&#xD;
          -  Must be willing to remain in the clinical research unit as required by the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of other study drugs at the time of enrollment, or within 5 half-lives of&#xD;
             enrollment, or within 30 days, whichever is longer; or longer if required by local&#xD;
             regulations&#xD;
&#xD;
          -  History of hypersensitivity to the study treatment or to drugs of similar chemical&#xD;
             classes&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Women of child-bearing potential&#xD;
&#xD;
        Healthy Volunteers:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - In good health as determined by past medical history, physical examination, ECG,&#xD;
        laboratory tests, and urinalysis at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver disease or liver injury&#xD;
&#xD;
          -  Chronic infection with Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  History or presence of impaired renal function&#xD;
&#xD;
        Hepatically Impaired Subjects:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Hepatic impairment as defined by the Child-Pugh classification for severity of liver&#xD;
        disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe complications of liver disease within the preceding 3 months&#xD;
&#xD;
          -  Emergency room visit or hospitalization due to liver disease within the preceding 3&#xD;
             months for mildly and moderately hepatically impaired subjects, and within the&#xD;
             preceding 1 month for severely hepatically impaired subjects&#xD;
&#xD;
          -  Subject has received liver transplant at any time in the past and is on&#xD;
             immunosuppressant therapy&#xD;
&#xD;
          -  Acute Hepatitis B or Hepatitis C infection&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17722</url>
    <description>Results for CCLJN452A2109 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=555</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LJN452</keyword>
  <keyword>tropifexor</keyword>
  <keyword>PK</keyword>
  <keyword>safety</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>hepatically impaired</keyword>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>Nonalcoholic Fatty Liver Disease</keyword>
  <keyword>NAFLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

